The endovascular treatment of juxta-renal XXXX using fenestrated endograft: early and mid-term results.

@entity1 @entity1070 @entity1011 @entity1950 @entity7943 @entity1028
AIM: To evaluate the early and mid term results of the endovascular treatment of juxta-renal @entity1028 (j-AAA) using fenestrated endograft (FEVAR). METHODS: Between 2008 to 2013 all consecutive @entity1 underwent FEVAR using Cook-Zenith fenestrated endograft for treating j-AAA (proximal neck length <5mm) with renal aortic a/b angle < 60  , were prospectively collected in a database. Cardiovascular risk factors, co-morbidities, aortic- iliac morphological features, intra and post-procedural data were analyzed. Pre-operative FEVAR planning was performed by a thoraco-abdominal computer tomography angiography (CTA) and the 3D/Center Lumen Line reconstructions (3Mensio). Follow-up was conduced by duplex ultrasound (DUS)/ contrast enhancement DUS (CEUS) and/or CTA at 1,6,12-month and yearly thereafter. Early endpoints were: technical ( @entity1950 ) / clinical (CS) success, renal function worsening (>=  30% of pre- operative @entity1011 value) and @entity1070 . Mid term endpoints were: @entity1070 , target visceral vessels patency, j-AAA shrinkage, freedom from re-intervention and survival. RESULTS: Twenty @entity1 (M: 94.7%; mean age: 73.4  5.9 years; @entity7943 >= 3: 100%) were enrolled. The mean neck length and j-AAA diameter were 2    1.4mm (range: 0-4mm) and 54.9   5mm respectively. Eleven (55%) endograft with 2 fenestrations and a scallop, 8 (45%) with 3 fenestrations and a scallop and 1 (5%) with 1 fenestration and a scallop were implanted. Sixty-seven visceral vessels were re-vascularized. @entity1950 and CS were 100% and 95% respectively (1/20 30-day mortality). Peri-operative renal function worsening was observed in 15% of cases. The mean follow-up was 25  20 months (range: 2-72months). No @entity1070 or occlusion of target visceral vessels occurred. There was j-AAA shrinkage in 65% of @entity1 and no cases of j-AAA enlargement were observed. There were no FEVAR-related re-interventions. Survival at 12, 24 and 36 months were 89.4%, 80.5% e 80.5% respectively. CONCLUSION: According to our results, the endovascular treatment for j-AAA, with a/b angle < 60  , is safe and effective.
